Zhu Zhi, Gong Ying-Bo, Xu Hui-Mian
Department of Surgical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, China.
Chronic Dis Transl Med. 2020 Apr 23;6(3):147-157. doi: 10.1016/j.cdtm.2020.03.004. eCollection 2020 Sep.
Gastric cancer, which has a high incidence and poor prognosis, remains a therapeutic challenge. Recently, neoadjuvant therapy has attracted increasing attention due to high recurrence rate and low survival rate after resection in most patients with advanced stage. Clinical trials show that neoadjuvant approaches confer a significant survival advantage for resectable locally advanced gastric cancer. The specific advantages of chemoradiotherapy compared with chemotherapy have not been clarified; optimal regimens and cycles, particularly in the preoperative setting, should be studied further; and trials aimed at determining the role of targeted and immunological therapies should be conducted.
胃癌发病率高且预后较差，仍然是一个治疗难题。近年来，由于大多数晚期患者术后复发率高、生存率低，新辅助治疗受到越来越多的关注。临床试验表明，新辅助治疗方法可为可切除的局部晚期胃癌带来显著的生存优势。与化疗相比，放化疗的具体优势尚未明确；应进一步研究最佳方案和周期，尤其是在术前阶段；并且应开展旨在确定靶向治疗和免疫治疗作用的试验。
